Spot shows folks running as a symbol of how the health-challenged can chase their dreams because of Sanofi meds.

Discover Regeneron’s Q3 2025 earnings: strong Dupixent, Libtayo & EYLEA HD growth, R&D updates, plus key manufacturing and regulatory challenges.

With a new approach to creating thymus-targeted medicines for autoimmune diseases, Zag Bio has emerged from stealth with the ...

Mary E Brunkow, Fred Ramsdell and Shimon Sakaguchi are awarded this year's Nobel Prize in Medicine or Physiology. The Nobel Assembly at Karolinska Institutet announce the Nobel Prize in Physiology or ...

Sanofi India Limited ( ($IN:SANOFI) ) has shared an announcement. Sanofi India Limited has announced the appointment of Mr. Deepak Arora as the ...

Q3 2025 Earnings Call October 24, 2025 8:30 AM EDTCompany ParticipantsThomas Larsen - Head of Investor RelationsPaul Hudson - CEO ...

Pharmaceutical launches and increased demand for its blockbuster Dupixent drug lifted net sales by 7% in the third quarter.

Sanofi said new medicine generated sales of 1 billion euros, up 57% from the same period last year. It said sales of the anti-inflammatory treatment Dupixent--developed jointly with Regeneron--jumped ...

Sanofi will employ Medidata’s expertise and capabilities in decentralized clinical trials as part of this new enterprise agreement. Medidata will also provide strategic consulting and end-to-end ...

The drug’s success in a Phase 2 study in alpha-1 antitrypsin deficiency “validates” Sanofi’s 2024 acquisition of Inhibrx, ...